These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 8011536)
1. Successful re-treatment of an anti-interferon resistant polycythaemia vera patient with lymphoblastoid interferon-alpha N1 and in vitro studies on the specificity of the antibodies. Brand CM; Leadbeater L; Budiman R; Lechner K; Gisslinger H Br J Haematol; 1994 Jan; 86(1):216-8. PubMed ID: 8011536 [TBL] [Abstract][Full Text] [Related]
2. Interferon-alpha neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-alpha n3. Zhao XX; Hua J; Smith T; Ferencz-Biro K; Liao MJ; Rashidbaigi A Hum Antibodies; 1997; 8(3):129-36. PubMed ID: 9322083 [TBL] [Abstract][Full Text] [Related]
3. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. Ross C; Svenson M; Hansen MB; Vejlsgaard GL; Bendtzen K J Clin Invest; 1995 May; 95(5):1974-8. PubMed ID: 7738163 [TBL] [Abstract][Full Text] [Related]
4. Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-alpha subtypes. Brand CM; Leadbeater L; Bellati G; Marotta F; Ideo G J Interferon Res; 1993 Apr; 13(2):121-5. PubMed ID: 7685368 [TBL] [Abstract][Full Text] [Related]
5. Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha. Wussow PV; Jakschies D; Freund M; Hehlmann R; Brockhaus F; Hochkeppel H; Horisberger M; Deicher H Br J Haematol; 1991 Jun; 78(2):210-6. PubMed ID: 2064959 [TBL] [Abstract][Full Text] [Related]
6. Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations. Antonelli G; Currenti M; Turriziani O; Dianzani F J Infect Dis; 1991 Apr; 163(4):882-5. PubMed ID: 1901335 [TBL] [Abstract][Full Text] [Related]
7. Response to sequential treatment with lymphoblastoid interferon-alpha in patients with Ph+ chronic myeloid leukemia unresponsive to recombinant interferon-alpha (rIFN alpha 2a) and neutralizing-rIFN alpha 2a antibodies negative. Russo D; Candoni A; Grattoni R; Minisini R; Rosti G Haematologica; 1997; 82(3):348-50. PubMed ID: 9234589 [TBL] [Abstract][Full Text] [Related]
8. Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia. Scagnolari C; Casato M; Bellomi F; De Pisa F; Turriziani O; Coviello R; Pirro MR; Dianzani F; Antonelli G Clin Diagn Lab Immunol; 2003 Jan; 10(1):70-7. PubMed ID: 12522042 [TBL] [Abstract][Full Text] [Related]
9. Treatment with natural human interferon alpha of a CML-patient with antibodies to recombinant interferon alpha-2b. Freund M; von Wussow P; Knüver-Hopf J; Mohr H; Pohl U; Exeriede G; Link H; Wilke HJ; Poliwoda H Blut; 1988 Nov; 57(5):311-5. PubMed ID: 3196882 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of recombinant interferon-alpha in polycythaemia vera. Oztürk A; Günay A; Uskent N Acta Haematol; 1998; 99(2):89-91. PubMed ID: 9554456 [TBL] [Abstract][Full Text] [Related]
11. Long-term therapeutic efficacy and toxicity of recombinant interferon-alpha 2a in polycythaemia vera. Foa P; Massaro P; Caldiera S; LaTargia ML; Iurlo A; Clerici C; Fornier M; Bertoni F; Maiolo AT Eur J Haematol; 1998 May; 60(5):273-7. PubMed ID: 9654155 [TBL] [Abstract][Full Text] [Related]
12. The in vitro and in vivo effect of recombinant interferon alpha-2a on circulating haemopoietic progenitors in polycythaemia vera. Castello G; Lerza R; Cerruti A; Cavallini D; Bogliolo G; Pannacciulli I Br J Haematol; 1994 Jul; 87(3):621-3. PubMed ID: 7993806 [TBL] [Abstract][Full Text] [Related]
13. Interferon antibodies in thrombocythemia. Merup M; Engman K; Paul C J Interferon Res; 1994 Aug; 14(4):187-9. PubMed ID: 7822871 [No Abstract] [Full Text] [Related]
14. [Treatment with lymphoblastoid alpha interferon in patients with chronic myeloid leukemia refractory to recombinant interferon alpha 2]. Steegmann JL; Granados E; Vázquez L; de la Cámara R; Peñarrubia MJ; Fernández-Contreras E; Quiroga JA; Fernández Rañada JM Sangre (Barc); 1998 Oct; 43(5):443-6. PubMed ID: 9868341 [TBL] [Abstract][Full Text] [Related]
15. The role of alpha-interferon in essential thrombocythaemia, polycythaemia vera and myelofibrosis with myeloid metaplasia (MMM): a concise update. Sacchi S Leuk Lymphoma; 1995 Sep; 19(1-2):13-20. PubMed ID: 8574158 [TBL] [Abstract][Full Text] [Related]
16. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors. Oberg K; Alm GV J Interferon Res; 1989 Sep; 9 Suppl 1():S45-9. PubMed ID: 2809277 [TBL] [Abstract][Full Text] [Related]
17. Natural leukocyte interferon-alpha therapy in patients with chronic granulocytic leukemia who have antibody-mediated resistance to treatment with recombinant interferon-alpha. Tefferi A; Grendahl DC Am J Hematol; 1996 Jul; 52(3):231-3. PubMed ID: 8756097 [TBL] [Abstract][Full Text] [Related]
18. Relief of intractable pruritus in polycythemia vera with recombinant interferon alfa. Finelli C; Gugliotta L; Gamberi B; Vianelli N; Visani G; Tura S Am J Hematol; 1993 Aug; 43(4):316-8. PubMed ID: 8372816 [TBL] [Abstract][Full Text] [Related]